Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Tnkase Generic Name & Formulations
Legal Class
Rx
General Description
Tenecteplase 50mg/vial; lyophilized pwd for IV inj after reconstitution.
Pharmacological Class
Tissue plasminogen activator (tPA).
How Supplied
Vial—1 (w. diluent, supplies)
Manufacturer
Tnkase Indications
Indications
To reduce mortality associated with acute myocardial infarction (AMI).
Tnkase Dosage and Administration
Adult
Start treatment soon after onset of AMI symptoms. Give as single IV bolus over 5 seconds. <60kg: 30mg; ≥60kg–<70kg: 35mg; ≥70kg–<80kg: 40mg; ≥80kg–<90kg: 45mg; ≥90kg: 50mg. Max: 50mg.
Children
Not recommended.
Tnkase Contraindications
Contraindications
Active internal bleeding. History of cerebrovascular accident. Intracranial or intraspinal surgery or trauma within 2 months. Intracranial neoplasm, arteriovenous malformation, or aneurysm. Bleeding diathesis. Severe uncontrolled hypertension.
Tnkase Boxed Warnings
Not Applicable
Tnkase Warnings/Precautions
Warnings/Precautions
Avoid noncompressible arterial puncture, internal jugular and subclavian venous puncture, IM injections and nonessential handling of patient during treatment. Increased bleeding risk at puncture sites; minimize arterial and venous punctures. Increased risk of complications with recent major surgery, cerebrovascular disease, GI or GU bleeding, recent trauma, hypertension (systolic BP ≥180mm Hg and/or diastolic BP ≥110mm Hg), acute pericarditis, subacute bacterial endocarditis, hemostatic defects, hepatic dysfunction, pregnancy, hemorrhagic ophthalmic conditions, septic thrombophlebitis, elderly. Increased risk of thromboembolic events in those with left heart thrombus (eg, mitral stenosis, A-fib). Pregnancy. Nursing mothers.
Tnkase Pharmacokinetics
See Literature
Tnkase Interactions
Interactions
Increased bleeding risk with heparin, vitamin K antagonists, aspirin, dipyridamole, GP IIb/IIIa inhibitors. May interfere with coagulation tests.
Tnkase Adverse Reactions
Adverse Reactions
Bleeding (may be serious), cardiogenic shock, arrhythmias, AV block, pulmonary edema, heart failure, cardiac arrest, recurrent MI, myocardial rupture, cardiac tamponade, pericarditis, pericardial effusion, mitral regurgitation, thromboembolism, electromechanical dissociation, nausea, vomiting, hypotension, fever; hypersensitivity reactions (monitor), cholesterol embolism.
Tnkase Clinical Trials
See Literature
Tnkase Note
Not Applicable
Tnkase Patient Counseling
See Literature
